Mesoblast (FRA:LWB) 5-Year EBITDA Growth Rate : 15.80% (As of Jun. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Mesoblast 5-Year EBITDA Growth Rate?

Mesoblast's EBITDA per Share for the three months ended in Jun. 2024 was €0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 18.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 15.80% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 10.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Mesoblast was 21.10% per year. The lowest was -42.80% per year. And the median was -1.40% per year.

Competitive Comparison of Mesoblast's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Mesoblast's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mesoblast's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Mesoblast's 5-Year EBITDA Growth Rate falls into.

Mesoblast 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Mesoblast (FRA:LWB) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Mesoblast 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Mesoblast's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (FRA:LWB) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

MEOBF:USA MESO:USA LWB:Germany MSB:Australia

Address

55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Mesoblast Headlines

No Headlines